Rhythm Pharmaceuticals, Inc. (RYTM): Capital Expenditures
$953.0K
Year ended 2025-12-31
+50.2%
3-year compound annual growth
+34.8%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $953.0K | n/a | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $0 | -100.0% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $47.0K | -83.3% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $281.0K | -35.3% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $434.0K | +102.8% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $214.0K | -93.7% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $3.38M | +368.8% | 2021-03-01, From 2019-01-01 |
| 2018-12-31 | $722.0K | +442.9% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $133.0K | -87.4% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $1.06M | n/m | 2019-03-08, From 2016-01-01 |
| 2015-12-31 | $17.0K | n/a | 2018-03-12, From 2015-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $953.0K | n/a |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $13.15M | -55.7% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $670.0K | +230.0% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $3.57M | +160.5% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $16.44M | -4.7% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $229.0K | +69.6% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $187.0K | n/a |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $998.0K | +103.7% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $2.37M | -38.6% |
Compare RYTM, MRVI, STOK, LFVN side by side · Screen every company in Pharmaceutical Preparations ↗